Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Small Cell Lung Carcinoma 30Burkitt Lymphoma 12Lung Neoplasms 11Leukemia, Myeloid, Acute 11Recurrence 10Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Lymphoma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Carcinoma, Non-Small-Cell Lung 7Neuroblastoma 4Lymphoma, B-Cell 4Leukemia 4Wilms Tumor 3Sarcoma, Ewing 3Plasmablastic Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, T-Cell 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Immunoblastic Lymphadenopathy 3Ganglioneuroblastoma 3Teratoma 2Sarcoma 2

Interventions

sacituzumab govitecan 1pembrolizumab 1atezolizumab 1PT-100 dipeptide 1PM 01183 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × Etoposide × 90 days × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡